Volcano Steps Up in Vulnerable Plaque By Buying Jomed's IVUS Business

For Volcano Therapeutics, the addition of Jomed's IVUS business is both an addition to and diversification beyond its current play in thermography as a diagnostic tool to detect vulnerable plaque.

For VolcanoTherapeutics Inc., the addition of Jomed NV 's IVUS business is both an addition to and diversification beyond its current play in thermography as a diagnostic tool to detect vulnerable plaque [See Deal].

As we noted in our profile of Volcano (see "Vulnerable Plaque Heats Up," IN VIVO, October 2002 Also see "Vulnerable Plaque Heats Up" - In Vivo, 1 October, 2002.), key to the company's technology portfolio is a package of spectral analysis software, licensed from the Cleveland Clinic Foundation and called the Virtual Histology platform, that uses a radio frequency (RF) back scatter signal from IVUS to create automatic boundaries and geometry of the vessel [See Deal]. This allows for plaque characterization through what Volcano calls pseudo-histology, further enabling real-time diagnosis of vulnerable plaque

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By 

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.